We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Rapid Technique Described for Detection of KRAS Mutations in Pathology Specimens

By LabMedica International staff writers
Posted on 20 Jun 2016
Print article
Image: Assay principles: Unpurified PCR product is added to a micro well containing probe-conjugated microbeads. A wild-type target hybridizes efficiently to both probes, inducing bead aggregation. Hybridization of a mutant target to the discriminating probe is unfavorable; therefore, the beads remain dispersed. An image of each micro well is obtained and processed to generate a saturation value corresponding to the extent of aggregation (Photo courtesy of The Journal of Molecular Diagnostics).
Image: Assay principles: Unpurified PCR product is added to a micro well containing probe-conjugated microbeads. A wild-type target hybridizes efficiently to both probes, inducing bead aggregation. Hybridization of a mutant target to the discriminating probe is unfavorable; therefore, the beads remain dispersed. An image of each micro well is obtained and processed to generate a saturation value corresponding to the extent of aggregation (Photo courtesy of The Journal of Molecular Diagnostics).
A recent paper described a rapid and inexpensive method for detecting KRAS mutations in clinical biopsy specimens of lung and colorectal cancers.

KRAS mutations have emerged as powerful predictors of response to targeted therapies in the treatment of lung and colorectal cancers; thus, prospective KRAS genotyping is essential for selecting appropriate treatment. Conventional mutation testing technologies are not ideal for routine clinical screening, as they often involve complex, time-consuming processes and/or costly instrumentation.

Investigators at the University of Virginia (Charlottesville, USA) recently described a method that uses hybridization-induced aggregation (HIA) technology for mutation detection (HIAMD), which enables the detection of common KRAS mutations in less than 10 minutes following PCR amplification.

The method is an extension of hybridization-induced aggregation (HIA) technology, whereby the hybridization of a specific DNA target to a pair of oligonucleotide probes immobilized on the surface of microbeads, tethers the microbeads together and induces aggregation. A digital image of the hybridization micro well is used for quantifying the extent of aggregation in terms of image saturation, which allows for a quantitative representation of hybridization efficiency.

The HIAMD method uses samples processed according to current clinical protocols and is compatible with the clinical laboratory workflow for sample preparation, which includes nucleic acid extraction and PCR amplification. After amplification, HIAMD analysis for the detection of all common KRAS mutations (located in codons 12 and 13) is complete in less than10 minutes, which includes approximately three minutes for thermal denaturation and snap-cool, approximately one minute for pipetting the reagents (sample, buffer, and beads) onto the chip, two minutes for the hybridization assay, and approximately three minutes for image analysis. Sequencing analysis, on the other hand, requires further sample preparation, including a tedious PCR cleanup step, and has a turnaround time in the order of days. The simple instrumentation needed for HIAMD keeps the method very low in cost (approximately 2500 USD for all equipment, compared to approximately 100,000 USD for sequencing instrumentation).

The investigators evaluated the clinical utility of the HIAMD method for the analysis of 20 lung and colon tumor pathology specimens. They observed a 100% correlation between the KRAS mutation statuses determined by HIAMD and by classical sequencing. In addition, they were able to detect KRAS mutations in a background of 75% wild-type DNA—a finding consistent with that reported for sequencing.

"These results indicate the validity of HIAMD as a mutation-testing technology suitable for practical clinical testing," said senior author Dr. Kimberly A. Kelly, professor of biomedical engineering at the University of Virginia. "Importantly, the analysis is performed in a manner that is both rapid and cost effective. The current direction of clinical oncology research suggests that a technology such as HIAMD will continue to be a highly relevant and valued analytical tool for the facilitation of individualized therapeutic strategies, and the successes here indicate the potential to apply this technology for the routine analysis of other important genetic markers."

"Targeted therapies are a growing trend in basic and clinical cancer research, and for good reason - the potential for improved treatment outcomes and cost savings is tremendous," said Dr. Kelly. "However, the effective implementation of a targeted therapeutic regime requires a practical means for preemptive molecular characterization of the cancer. In an effort to fulfill the unmet clinical demand for a methodology amenable to the requirements of routine testing, we developed a novel approach that provides simple, rapid, and inexpensive detection of point mutations."

The paper was published in the June 8, 2016, online edition of The Journal of Molecular Diagnostics.

Related Links:
University of Virginia


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.